NeuroVax (IR902) / Immune Response BioPharma - LARVOL DELTA

Indication bladder cancer added to the pipeline for the product NeuVax (Apthera, Inc) - NeuVax / Apthera

Corporate Pipeline Update • None

RXi pharmaceuticals to webcast presentation at BioCentury Future Leaders in the biotech industry conference (Businesswire) -

NeuVax is expected to enter P3 trials in H1 2011;

Oncology

RXi Pharmaceuticals announces positive NeuVax (E75) phase 2 efficacy results after 36 months of follow-up (Businesswire) - P2, N=182; NeuVax (E75) demonstrated statistical significance in 3-year disease free survival (DFS) in adjuvant breast cancer, with 0% recurrence in the treated group vs. 22.2% in the untreated group & also demonstrated an excellent safety & tolerability profile; Phase 3 PRESENT study expected to initiate in 1H ’12 under FDA approved Special Protocol Assessment (SPA)

Anticipated P3 trial initiation • Oncology

A Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis (clinicaltrials.gov) - P2/3; N=200; Recruiting; Sponsor: Immune Response BioPharma, Inc.; Not yet recruiting ➔ Recruiting; Trial completion date: Feb 2019 ➔ Mar 2023; Trial primary completion date: Feb 2019 ➔ Mar 2023

Enrollment open • Trial completion date • Trial primary completion date • MRI

A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis (clinicaltrials.gov) - P2b; N=150; Not yet recruiting; Sponsor: Immune Response BioPharma, Inc.; Trial completion date: Mar 2019 ➔ Mar 2022; Trial primary completion date: Mar 2019 ➔ Mar 2022

Trial completion date • Trial primary completion date

A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis (clinicaltrials.gov) - P1; N=12; Not yet recruiting; Sponsor: Immune Response BioPharma, Inc.; Trial completion date: Nov 2019 ➔ Nov 2024; Trial primary completion date: Nov 2019 ➔ Nov 2024

Clinical • Trial completion date • Trial primary completion date • FOXP3 • MRI

Characterization of Pm65, a new powdery mildew resistance gene on chromosome 2AL of a facultative wheat cultivar. (PubMed, Theor Appl Genet) - "A new powdery mildew resistance gene that can be readily used in wheat breeding, Pm65, was identified in the facultative wheat cultivar Xinmai 208 and mapped to the terminal region of chromosome 2AL...Coming from a high-yield potential cultivar, Pm65 can be directly used to enhance powdery mildew resistance in wheat. The newly developed SSR markers Xstars355 and Xstars356 have the potential to tag Pm65 for wheat improvement."

Journal